Conclusion. An ID specialist-led C. difficile testing approval process was feasible and associated with a significant decrease in HO-CDI testing and infection rates, due to enforcement of appropriate testing. ID specialists can provide a key role in enforcing appropriate C. difficile testing, but more experience is needed with respect to sustainability.

Disclosures. M. Y. Lin, Stryker (Sage Products); Research support in the form of contributed products, Research support. OpGen, Inc: Research support in the form of contributed products, Research support. CareFusion Foundation (now BD): Grant Investigator, Research grant.

975. Clostridium difficile Infection and Antibiotic Prescription Rates in the Community: Explaining the Gender Gap

Mariam Nouman, MD1, Julie Royer, MPH2, Hana Rac, PharmD3, Julie Ann Justo, PharmD, MS4, P Brandon Bookstaver, PharmD, FCCP, FIDSA, BCPS, AAHIVP,5, Sharon Weissman, MD1, Antton Maki Jr M.D., MBA, FRCP, FCAP, FACP6, Linda Bell, MD1, Katie Stilwel Waite, MPH7; Sangita Dash, MD8 and Majdi N. Al-Hasan, MBBS9,11. University of South Carolina School of Medicine, Columbia, South Carolina, 1Department of Medicine, Palmetto Health/ University of South Carolina Medical Group, Columbia, South Carolina, 3South Carolina Revenue and Fiscal Affairs Office, Columbia, South Carolina, 4Department of Clinical Pharmacy and Outcomes Sciences, University of South Carolina College of Pharmacy, Columbia, South Carolina and 5South Carolina Department of Health and Environmental Control, Columbia, South Carolina

Session: 126. Healthcare Epidemiology: The Poop Pager and Other Novel Perspectives on C. difficile in the Healthcare Setting

Friday, October 5, 2018: 10:30 AM

Background. Previous studies have reported higher incidence rates of community-associated Clostridium difficile infection (CA-CDI) in women than in men. This cross-sectional population-based study examines whether this difference in CA-CDI rates across genders is driven by or independent of antibiotic use.

Methods. Medicaid and State Employee Health Plan pharmacy claims for outpatient oral antibiotics and associated medical claims were utilized for estimation of community antibiotic prescription rates in South Carolina population. 18-64 years of age from January 1, 2015 to December 31, 2015. CA-CDI cases were identified from National Healthcare Safety Network (NHSN) and South Carolina Infectious Disease and Outbreak Network (SCION) through complete enumeration of South Carolina population each year and study period as above. Incidence rates of CA-CDI were reported in both men and women 18-39 and 40-64 years of age before and after adjustments for antibiotic prescription rates in the same gender and age group. The 95% confidence intervals (CI) were calculated to examine statistical difference in incidence rates across genders within the same age group.

Results. During the calendar year 2015, a total of 1,564 CA-CDI cases were identified in South Carolina residents 18-64 years of age. The incidence rate of CA-CDI per 100,000 person-years was higher in women than in men age groups 18–39 years (37.3 [95% CI: 32.8–41.8] vs. 21.0 [95% CI: 17.6–24.4]) and 40–64 years (86.4 [95% CI: 80.1–92.8] vs. 56.6 [95% CI: 51.2–61.9]). Similarly, antibiotic prescription rates per 100 person-years were higher in women than men in the 2 respective age groups (118.8 [95% CI: 118.3–119.3] vs. 54.3 [95% CI: 53.9–54.8] and 130.4 [95% CI: 129.8–130.9] vs. 83.8 [95% CI: 83.3–84.4]). After adjustments for antibiotic prescriptions, there was no significant difference in the incidence rates of CA-CDI per 100,000 prescriptions between women and men 18–39 years of age (31.4 [95% CI: 27.6–35.2] vs. 21.0 [95% CI: 17.6–24.4]) and 40–64 years old (66.3 [95% CI: 61.5–71.2] vs. 67.5 [95% CI: 61.1–73.8]).

Conclusion. Higher crude incidence rates of CA-CDI in women are likely due to higher outpatient antibiotic prescription rates in women when compared with men. The difference in CA-CDI rates across genders is driven by or independent of antibiotic use.

Disclosures. P. B. Bookstaver, CutisPharma: Scientific Advisor, <$1,000. Melinta Therapeutics: Speaker’s Bureau, <$1,000.

976. Clostridium difficile Colonization Molecular Epidemiology and Anti-toxin Serological Responses in Healthy Infants: A Prospective Cohort Study

Larry Kociszewski, MD, MSC1; Cieran P. Kelly, MD2; Robyn Espnosa, MPH1; Maria Budz, MFT3; Aaksh Jhajj, BSc, Egon Oster, MD, PhD4; Robert Tanz, MD5; Xinhua Chen, PhD3 and Dale N Gerding, MD, FIDSA6, 1Pediatrics, Northwestern Feinberg School of Medicine, Chicago, Illinois, 2Beth Israel Deaconess Medical Center, Boston, Massachusetts, 3Ann and Robert H. Lurie Children’s Hospital of Chicago, Chicago, Illinois, 4Northwestern University Feinberg School of Medicine, Chicago, Illinois and 5Children’s Memorial Hospital, Chicago, Illinois, 6Loyola University, Hines, Illinois

Session: 126. Healthcare Epidemiology: The Poop Pager and Other Novel Perspectives on C. difficile in the Healthcare Setting

Friday, October 5, 2018: 10:30 AM

Background. Infant C. difficile colonization is common, but the molecular epidemiology and immunologic consequences of colonization are poorly understood.

Methods. In this prospective cohort study of healthy infants, serial stools collected between 1-2 and 9–12 month olds were tested for glutamate dehydrogenase (detects nontoxigenic or toxigenic C. difficile [TCD]), tcdB PCR (detects TCD), and cultured for C. difflile. Isolates underwent whole genome sequencing and multilocus sequence typing (MLST). C. difficile. Strains were identified by single nucleotide variant (SNV) analysis. TCD was confirmed by BLAST identification of tcdA/tcdB. Serum collected at 9–12 month olds underwent ELISA for measurement of IgA, IgG, and IgM against TCD toxins A and B. For comparison, anti-toxin IgM was measured in cord blood of 50 consecutive full-term deliveries (unrelated to study infants). Arbitrary ELISA units were compared by Wilcoxon rank-sum test.

Results. Among 32 infants, 16 (50%) had at least one TCD+ stool, 12 of whom were colonized at least 1 week prior to serology measurements (Figures 1 and 2). A variety of STs were identified, and evidence of putative in-home (enrolled siblings) and outpatient clinic transmission was identified (Figure 3). Infants with TCD colonization had significantly greater levels of anti-toxin IgA and IgG compared with non-colonized infants and IgM compared with unrelated cord blood (Table 1).

Conclusion. Infant C. difficile colonization is a dynamic process with variable strain types and duration. Outpatient clinics may be a C. difficile reservoir for some patients. TCD colonization is associated with a humoral immune response against toxins A and B, but whether natural TCD immunization protects against CDI later in life requires further investigation.

Table 1: Anti-toxin Serology (Arbitrary ELISA Units)

| Group                          | Tox A IgA | Tox A IgG | Tox A IgM | Tox B IgA | Tox B IgG | Tox B IgM |
|-------------------------------|-----------|-----------|-----------|-----------|-----------|-----------|
| Not colonized with TCD        | 1.37      | 10.14     | 2.74      | 0.8       | 6.50      | 6.14      |
| Colonized with TCD for at least 1 month | 4.23*     | 3.78*     | 2.54      | 1.73*     | 20.76*    | 5.96      |
| Cord Blood                     |           |           |           |           |           |           |
| (n = 16)                       | 10.81^    |           |           |           |           | 8.34^     |

*P < 0.05 (colonized vs. non-colonized); ^P < 0.05 (colonized vs. cord blood)

Figure 1: Infant Classification

Figure 2: Chronology and Results of Infant Stool C. difficile Testing

Figure 3: Molecular Epidemiology of Infant C. difficile Isolates